ShuguangWang (Talk | contribs) |
ShuguangWang (Talk | contribs) |
||
Line 91: | Line 91: | ||
z-index: 1; | z-index: 1; | ||
background-color: #EEEEEE; | background-color: #EEEEEE; | ||
− | |||
− | |||
box-shadow: 0 5px 15px #CCCCCC; | box-shadow: 0 5px 15px #CCCCCC; | ||
display: none; | display: none; | ||
Line 154: | Line 152: | ||
} | } | ||
− | .daohang a:hover span{ | + | .daohang a:hover span { |
− | transform: rotateY(180deg); | + | transform: rotateY(180deg); |
− | -webkit-transform: rotateY(180deg); | + | -webkit-transform: rotateY(180deg); |
− | -moz-transform: rotateY(180deg); | + | -moz-transform: rotateY(180deg); |
− | -o-transform: rotateY(180deg); | + | -o-transform: rotateY(180deg); |
-ms-transform: rotateY(180deg); | -ms-transform: rotateY(180deg); | ||
− | transition: all 0.5s ease-in-out; | + | transition: all 0.5s ease-in-out; |
− | -webkit-transition: all 0.5s ease-in-out; | + | -webkit-transition: all 0.5s ease-in-out; |
− | -moz-transition: all 0.5s ease-in-out; | + | -moz-transition: all 0.5s ease-in-out; |
-o-transition: all 0.5s ease-in-out; | -o-transition: all 0.5s ease-in-out; | ||
} | } | ||
Line 244: | Line 242: | ||
.daohangyi { | .daohangyi { | ||
− | font-size: | + | font-size: 12px; |
} | } | ||
} | } | ||
Line 269: | Line 267: | ||
.daohangyi img { | .daohangyi img { | ||
display: none; | display: none; | ||
+ | } | ||
+ | |||
+ | .daohang .longName .item:before { | ||
+ | width: 150px; | ||
+ | left: 20px; | ||
+ | } | ||
+ | |||
+ | .daohang .longName .item:hover:after { | ||
+ | width: 150px; | ||
+ | left: 20px; | ||
} | } | ||
} | } | ||
Line 292: | Line 300: | ||
width: 80%; | width: 80%; | ||
/* height: auto; */ | /* height: auto; */ | ||
− | margin: 20px | + | margin: 20px 40px 0 0; |
/* right: 2%; */ | /* right: 2%; */ | ||
/* top: 90px; */ | /* top: 90px; */ | ||
− | padding: | + | padding: 50px 3%; |
float: right; | float: right; | ||
/* position: relative; */ | /* position: relative; */ | ||
Line 308: | Line 316: | ||
.cebian { | .cebian { | ||
− | width: | + | width: 180px; |
/* height: 80vh; */ | /* height: 80vh; */ | ||
float: left; | float: left; | ||
Line 317: | Line 325: | ||
/* border:2px solid black */ | /* border:2px solid black */ | ||
/* background-color: #323643 */ | /* background-color: #323643 */ | ||
+ | } | ||
+ | |||
+ | .zhengwen p{ | ||
+ | text-align: justify !important; | ||
+ | font-family: 'Times New Roman',Helvetica,'Open Sans', Arial, sans-serif !important; | ||
+ | color: #3B3B3B; | ||
+ | font-size: 26px !important; | ||
+ | padding-right: 20px; | ||
} | } | ||
Line 327: | Line 343: | ||
.h1 { | .h1 { | ||
− | height: | + | height: 80px; |
− | line-height: | + | line-height: 80px; |
font-weight: bold; | font-weight: bold; | ||
font-family: 'Product Sans', sans-serif; | font-family: 'Product Sans', sans-serif; | ||
− | font-size: | + | font-size: 40px; |
− | color: | + | color: #3B3B3B; |
− | border-bottom: | + | border-bottom: 2px solid #676767; |
− | /* margin: | + | margin-bottom: 20px; |
+ | } | ||
+ | |||
+ | .h2 { | ||
+ | height: 40px; | ||
+ | line-height: 40px; | ||
+ | font-weight: bold; | ||
+ | /* font-weight: bold; */ | ||
+ | font-family: 'Product Sans', sans-serif; | ||
+ | font-size: 30px; | ||
+ | color: #484848; | ||
+ | /* margin-bottom: 20px; */ | ||
+ | } | ||
+ | |||
+ | .h3 { | ||
+ | height: 30px; | ||
+ | line-height: 30px; | ||
+ | font-weight: bold; | ||
+ | /* font-weight: bold; */ | ||
+ | font-family: 'Product Sans', sans-serif; | ||
+ | font-size: 24px; | ||
+ | color: #484848; | ||
+ | /* margin-bottom: 20px; */ | ||
} | } | ||
Line 450: | Line 488: | ||
<style> | <style> | ||
#float01 {} | #float01 {} | ||
− | + | ||
− | + | #float02 {} | |
− | + | ||
− | + | div.floatCtro { | |
− | + | width: 100%; | |
− | + | /* height: auto; */ | |
− | + | margin: 0; | |
− | + | position: relative; | |
− | + | background: #fff; | |
− | + | ||
− | + | } | |
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
.daohangyi { | .daohangyi { | ||
− | font-size: 14px; | + | display: block; |
+ | width: 100%; | ||
+ | /* height: auto; */ | ||
+ | /* text-align: left !important; */ | ||
+ | color: #ffffff !important; | ||
+ | font-size: 16px; | ||
+ | padding:0; | ||
+ | background-color: #323643; | ||
+ | border-bottom: 1px solid black; | ||
+ | padding:0 3%; | ||
+ | text-decoration: none !important; | ||
+ | } | ||
+ | |||
+ | div.floatCtro .daohanger { | ||
+ | width: 100%; | ||
+ | text-align: left !important; | ||
+ | height: auto; | ||
+ | line-height: 25px; | ||
+ | font-family: Arial; | ||
+ | font-size: 14px !important; | ||
+ | color: #676767; | ||
+ | margin: 0; | ||
+ | padding:10px 8%; | ||
+ | cursor: pointer; | ||
+ | background: #fff; | ||
+ | } | ||
+ | |||
+ | div.floatCtro a { | ||
+ | display: inline-block; | ||
+ | display: none; | ||
+ | width: 100%; | ||
+ | height: 40px; | ||
+ | padding:10px 8%; | ||
+ | /* margin: 10px 0 0 0; */ | ||
+ | background: #FFF; | ||
+ | color: #000 !important; | ||
+ | vertical-align: middle; | ||
+ | cursor: pointer; | ||
+ | } | ||
+ | |||
+ | div.floatCtro a span { | ||
+ | display: block; | ||
+ | height: auto; | ||
+ | text-align: left !important; | ||
+ | line-height: 18px; | ||
+ | font-family: Arial; | ||
+ | font-size: 16px; | ||
+ | } | ||
+ | |||
+ | div.floatCtro a:hover { | ||
+ | /* background: #76b39d; */ | ||
+ | color: #EA0D04 !important; | ||
+ | zoom: 1; | ||
} | } | ||
− | + | ||
− | + | /* .cebian a:hover { | |
− | + | color: #f6eee0 !important; | |
− | + | } */ | |
+ | |||
+ | div.floatCtro .daohanger:hover { | ||
+ | /* background: #76b39d; */ | ||
+ | color: #1fa67a; | ||
+ | text-decoration: underline !important; | ||
+ | } | ||
+ | |||
+ | div.floatCtro .daohanger.cur { | ||
+ | /* background: #1fa67a; */ | ||
+ | color: #1fa67a; | ||
+ | } | ||
+ | |||
+ | .biaoti { | ||
+ | display: inline-block; | ||
+ | margin: 8px 0; | ||
+ | /* width: 50%; */ | ||
+ | /* margin-left: 6%; */ | ||
+ | /* text-align: center; */ | ||
+ | text-decoration: none !important; | ||
+ | } | ||
+ | |||
.daohangyi img { | .daohangyi img { | ||
+ | display: inline-block; | ||
+ | width: 12px; | ||
+ | height: 12px; | ||
+ | vertical-align: middle; | ||
+ | background-size: 100% 100%; | ||
+ | |||
+ | } | ||
+ | .cebian div:hover img{ | ||
+ | transform: rotateY(180deg); | ||
+ | -webkit-transform: rotateY(180deg); | ||
+ | -moz-transform: rotateY(180deg); | ||
+ | -o-transform: rotateY(180deg); | ||
+ | -ms-transform: rotateY(180deg); | ||
+ | transition: all 0.5s ease-in-out; | ||
+ | -webkit-transition: all 0.5s ease-in-out; | ||
+ | -moz-transition: all 0.5s ease-in-out; | ||
+ | -o-transition: all 0.5s ease-in-out; | ||
+ | } | ||
+ | .cebian a:hover img{ | ||
+ | transform: rotate(360deg); | ||
+ | -webkit-transform: rotate(360deg); | ||
+ | -moz-transform: rotate(360deg); | ||
+ | -o-transform: rotate(360deg); | ||
+ | -ms-transform: rotate(360deg); | ||
+ | transition: all 0.5s ease-in-out; | ||
+ | -webkit-transition: all 0.5s ease-in-out; | ||
+ | -moz-transition: all 0.5s ease-in-out; | ||
+ | -o-transition: all 0.5s ease-in-out; | ||
+ | } | ||
+ | |||
+ | @media screen and (max-width: 1200px) { | ||
+ | |||
+ | .cebian { | ||
+ | width: 15%; | ||
+ | } | ||
+ | |||
+ | .zhengwen { | ||
+ | margin: 20px 20px 0 0; | ||
+ | |||
+ | .daohangyi { | ||
+ | font-size: 14px; | ||
+ | } | ||
+ | .daohangyi img { | ||
+ | display: none; | ||
+ | } | ||
+ | } | ||
+ | |||
+ | @media screen and (max-width: 900px) { | ||
+ | |||
+ | .daohangyi img { | ||
+ | display: none; | ||
+ | } | ||
+ | |||
+ | .laoshi img { | ||
+ | height: 30vh; | ||
+ | } | ||
+ | } | ||
+ | </style> | ||
+ | <!-- 折叠框CSS --> | ||
+ | <style> | ||
+ | .collapseDiv { | ||
+ | color: #333; | ||
+ | border-radius: 4px; | ||
+ | background-color: #F3F3F3; | ||
+ | border: 1px solid transparent; | ||
+ | border-color: #ddd; | ||
+ | box-shadow: 0 1px 1px #F3F3F3; | ||
+ | margin-top: 5px; | ||
+ | margin-bottom: 0; | ||
+ | } | ||
+ | .collapseDiv label { | ||
+ | cursor: pointer; | ||
+ | font-size: 24px !important; | ||
+ | /* font-weight: bold; */ | ||
+ | color: green !important; | ||
+ | border-color: #F3F3F3 !important; | ||
+ | padding: 5px 15px 5px 18px !important; | ||
+ | background-color: #f5f5f5 !important; | ||
+ | margin: 0 !important; | ||
+ | border-radius: 5px !important; | ||
+ | } | ||
+ | |||
+ | #zhedie-toggle1, | ||
+ | #zhedie-toggle2, | ||
+ | #zhedie-toggle3, | ||
+ | #zhedie-toggle4 { | ||
display: none; | display: none; | ||
− | } | + | } |
+ | |||
+ | #zhedie1, | ||
+ | #zhedie2, | ||
+ | #zhedie3, | ||
+ | #zhedie4 { | ||
+ | display: none; | ||
+ | font-size: 18px; | ||
+ | padding: 0 50px 0 50px; | ||
+ | width: 100%; | ||
+ | margin: 0; | ||
+ | color: black; | ||
+ | } | ||
+ | |||
+ | #zhedie-toggle1:checked+#zhedie1, | ||
+ | #zhedie-toggle2:checked+#zhedie2, | ||
+ | #zhedie-toggle3:checked+#zhedie3, | ||
+ | #zhedie-toggle4:checked+#zhedie4 { | ||
+ | display: block; | ||
+ | } | ||
+ | |||
− | . | + | |
− | + | ||
+ | .collapse_body { | ||
+ | background-color: #fff; | ||
+ | position: relative; | ||
+ | height: 0; | ||
+ | overflow: hidden; | ||
+ | -webkit-transition-timing-function: ease; | ||
+ | -o-transition-timing-function: ease; | ||
+ | transition-timing-function: ease; | ||
+ | -webkit-transition-duration: .35s; | ||
+ | -o-transition-duration: .35s; | ||
+ | transition-duration: .35s; | ||
+ | -webkit-transition-property: height, visibility; | ||
+ | -o-transition-property: height, visibility; | ||
+ | transition-property: height, visibility | ||
+ | } | ||
+ | .collapse_content { | ||
+ | font-size: 20px; | ||
+ | border-top: 1px solid #ddd; | ||
+ | background-color: #fff; | ||
+ | padding: 15px; | ||
} | } | ||
− | |||
</style> | </style> | ||
− | |||
</head> | </head> | ||
Line 617: | Line 741: | ||
<a class="item" href="https://2018.igem.org/Team:HZAU-China/Improve">Improve</a> | <a class="item" href="https://2018.igem.org/Team:HZAU-China/Improve">Improve</a> | ||
<a class="item" href="https://2018.igem.org/Team:HZAU-China/InterLab">InterLab</a> | <a class="item" href="https://2018.igem.org/Team:HZAU-China/InterLab">InterLab</a> | ||
+ | <a class="item" href="https://2018.igem.org/Team:HZAU-China/Notebook">Notebook</a> | ||
+ | |||
</li> | </li> | ||
<li class="hiLight shortName"> | <li class="hiLight shortName"> | ||
Line 631: | Line 757: | ||
<span class="xjtPic"></span> | <span class="xjtPic"></span> | ||
</a> | </a> | ||
− | <a class="item" href="https://2018.igem.org/Team:HZAU-China/Safety"> | + | <a class="item" href="https://2018.igem.org/Team:HZAU-China/Safety">Safety</a> |
<a class="item" href="https://2018.igem.org/Team:HZAU-China/Human_Practices">Human Practices</a> | <a class="item" href="https://2018.igem.org/Team:HZAU-China/Human_Practices">Human Practices</a> | ||
<a class="item" href="https://2018.igem.org/Team:HZAU-China/Public_Engagement">Public Engagement</a> | <a class="item" href="https://2018.igem.org/Team:HZAU-China/Public_Engagement">Public Engagement</a> | ||
Line 644: | Line 770: | ||
<a class="item" href="https://2018.igem.org/Team:HZAU-China/Collaborations">Collaborations</a> | <a class="item" href="https://2018.igem.org/Team:HZAU-China/Collaborations">Collaborations</a> | ||
</li> | </li> | ||
− | <li class="shortName"> | + | <li class="hiLight shortName"> |
− | <a class="nav_head" href=" | + | <a class="nav_head" href="#"> |
<span>Parts</span> | <span>Parts</span> | ||
+ | <span class="xjtPic"></span> | ||
</a> | </a> | ||
+ | <a class="item" href="https://2018.igem.org/Team:HZAU-China/Basic_Part">Basic</a> | ||
+ | <a class="item" href="https://2018.igem.org/Team:HZAU-China/Composite_Part">Composite</a> | ||
</li> | </li> | ||
</ul> | </ul> | ||
Line 656: | Line 785: | ||
<!-- 正文 --> | <!-- 正文 --> | ||
<div class="zhengwen"> | <div class="zhengwen"> | ||
− | |||
<div id="float01" class="cur"> | <div id="float01" class="cur"> | ||
− | <div | + | <p>We gave the surface display system from BBa_J36850 a new function through displaying a RGD motif on |
− | + | the Lpp-OmpA. RGD motif can specifically bind to αVβ3, a biomarker of cancer cells<sup>1</sup>. We | |
+ | determine | ||
+ | the surface display site on the third loop of Lpp-OmpA through homology modelling (Figure 1). This | ||
+ | part is under the control of lac promoter. </p> | ||
+ | <div style="width: 30%; margin: 0px auto"> | ||
+ | <img src="https://static.igem.org/mediawiki/2018/5/5f/T--HZAU-China--Improve1.png" width=100% alt=""> | ||
+ | </div> | ||
+ | <p>Figure 1. Homology modelling result of Lpp-OmpA-RGD. Red arrow shows the location of RGD motif.</p> | ||
</div> | </div> | ||
<div id="float02"> | <div id="float02"> | ||
− | <div class=" | + | <p>Microscopy shows that E. coli expressed Lpp-OmpA-RGD induced by 0.1mM IPTG can bind to αVβ3-positive |
+ | MDA-MB-231 cell line. Red arrow points the location of bacteria (Figure 2). But cannot bind to | ||
+ | αVβ3-negative MCF7 cell line (Figure 3). We also use BBa_J36850 as a control. This strain cannot | ||
+ | bind to αVβ3-positive MDA-MB-231 cell line (Figure 4) and αVβ3-negative MCF7 cell line (Figure 5). | ||
+ | These results suggest that we successfully improve the part BBa_J36850. (Click here to see the | ||
+ | method)</p> | ||
+ | <div style="width: 90%; margin: 0px auto"> | ||
+ | <img src="https://static.igem.org/mediawiki/2018/b/b1/T--HZAU-China--Improve2.png" width=100% alt=""> | ||
+ | </div> | ||
+ | <p>Figure 2. αVβ3-positive MDA-MB-231 cell line was incubated with E. coli which constructively | ||
+ | expressed RFP and contained BBa_J36850. This improved part expressed RGD motif under the control of | ||
+ | lac promoter. </p> | ||
+ | <div style="width: 90%; margin: 0px auto"> | ||
+ | <img src="https://static.igem.org/mediawiki/2018/c/cf/T--HZAU-China--Improve3.png" width=100% alt=""> | ||
+ | </div> | ||
+ | <p>Figure 3. αVβ3-negative MCF7 cell line was incubated with E. coli which constructive expressed RFP | ||
+ | and contained BBa_J36850. This improved part expressed RGD motif under the control of lac promoter.</p> | ||
+ | <div style="width: 90%; margin: 0px auto"> | ||
+ | <img src="https://static.igem.org/mediawiki/2018/f/f7/T--HZAU-China--Improve4.png" width=100% alt=""> | ||
+ | </div> | ||
+ | <p>Figure 4. αVβ3-positive MDA-MB-231 cell line was incubated with E. coli which constructively | ||
+ | expressed RFP and contained BBa_J36850.</p> | ||
+ | <div style="width: 90%; margin: 0px auto"> | ||
+ | <img src="https://static.igem.org/mediawiki/2018/c/ce/T--HZAU-China--Improve5.png" width=100% alt=""> | ||
+ | </div> | ||
+ | <p>Figure 5. αVβ3-negative MCF7 cell line was incubated with E. coli which constructively expressed RFP | ||
+ | and contained BBa_J36850. </p> | ||
+ | <div class="collapseDiv"> | ||
+ | <label for="zhedie-toggle3">Method</label> | ||
+ | <input type="checkbox" id="zhedie-toggle3" /> | ||
+ | <div id="zhedie3" class="text-success text-left"> | ||
+ | <b>Preparation of Cells for Infection</b><br> | ||
+ | 1. Grow Hela GSDMD KO cells in a humidified 37 °C, 5% CO2 tissue-culture incubator.<br> | ||
+ | 2. Count the cells using a hemocytometer. Seed in 24-well (5 × 10^4 per well) and grow | ||
+ | overnight.<br> | ||
+ | <b>Preparation of Bacteria</b><br> | ||
+ | 1. Grow bacteria overnight 16 h in 2 mL LB in a 15-mL tube. Incubate at 37 °C in a shaking | ||
+ | incubator (200 rpm).<br> | ||
+ | 2. Subculture bacteria by transferring 300 μL of the overnight culture into 5 mL of LB in a | ||
+ | loosely capped 50-mL tube. Incubate at 37 °C in a shaking incubator (200 rpm) to late log | ||
+ | phase.<br> | ||
+ | 3. Pellet 1 mL of the Salmonella subculture by centrifugation at 1000 g in a microfuge for 2 | ||
+ | min at room temperature.<br> | ||
+ | 4. Remove 900 μL of supernatant and gently resuspend the pellet in 900 μL PBS.<br> | ||
+ | <b>Infection</b><br> | ||
+ | 1. Aspirate media and rinse the monolayer twice with PBS.<br> | ||
+ | 2. Inoculate cells with bacteria (MOI = 100) by adding bacteria directly to the cell-culture | ||
+ | supernatant.<br> | ||
+ | 3. Incubate for 2 h at 37 °C in 5% CO2.<br> | ||
+ | 4. Aspirate media and wash<br> | ||
+ | 5. Add fresh GM containing 100 μg/mL gentamicin and 16 μg/mL incubate at 37 °C in 5% CO2 for 2 | ||
+ | h.<br> | ||
+ | 6. Replace GM with fresh GM containing 20 μg/mL gentamicin for 1 h.<br> | ||
+ | 7.Add 16 μg/mL ATc for remainder of experiment.<br> | ||
+ | Observation is taken after 5 min, 30 min, 1.5 h.<br><br> | ||
+ | </div> | ||
+ | </div> | ||
</div> | </div> | ||
<div id="float03"> | <div id="float03"> | ||
− | <div class="h1"> | + | <div class="h1">Reference</div> |
− | + | <p>1 Park, S. H. et al. RGD Peptide Cell-Surface Display Enhances the Targeting and Therapeutic | |
+ | Efficacy of Attenuated Salmonella-mediated Cancer Therapy. Theranostics 6, 1672-1682, | ||
+ | doi:10.7150/thno.16135 (2016). | ||
+ | |||
+ | |||
+ | </p> | ||
+ | |||
</div> | </div> | ||
</div> | </div> | ||
Line 678: | Line 875: | ||
</a> | </a> | ||
<div class="daohangyi"> | <div class="daohangyi"> | ||
− | + | <span class="biaoti">Improve</span> | |
− | + | <span class="xsjPic"><img src="https://static.igem.org/mediawiki/2018/8/8d/T--HZAU-China--xjt.svg" alt=""></span> | |
</div> | </div> | ||
<div class="floatCtro"> | <div class="floatCtro"> | ||
− | <p class="daohanger"> | + | <!-- <p class="daohanger">Calibration</p> |
− | <p class="daohanger"> | + | <p class="daohanger">Cell Measurement</p> |
− | <p class="daohanger"> | + | <p class="daohanger">Summary</p> --> |
<a> | <a> | ||
<span>Back to Top</span> | <span>Back to Top</span> | ||
Line 691: | Line 888: | ||
<a class="daohangyi" href="https://2018.igem.org/Team:HZAU-China/InterLab"> | <a class="daohangyi" href="https://2018.igem.org/Team:HZAU-China/InterLab"> | ||
<span class="biaoti">InterLab</span> | <span class="biaoti">InterLab</span> | ||
+ | <span class="xsjPic"><img src="https://static.igem.org/mediawiki/2018/7/7c/T--HZAU-China--ysj.svg" alt=""></span> | ||
+ | </a> | ||
+ | <a class="daohangyi" href="https://2018.igem.org/Team:HZAU-China/Notebook"> | ||
+ | <span class="biaoti">Notebook</span> | ||
<span class="xsjPic"><img src="https://static.igem.org/mediawiki/2018/7/7c/T--HZAU-China--ysj.svg" alt=""></span> | <span class="xsjPic"><img src="https://static.igem.org/mediawiki/2018/7/7c/T--HZAU-China--ysj.svg" alt=""></span> | ||
</a> | </a> |
Revision as of 16:47, 16 October 2018
We gave the surface display system from BBa_J36850 a new function through displaying a RGD motif on the Lpp-OmpA. RGD motif can specifically bind to αVβ3, a biomarker of cancer cells1. We determine the surface display site on the third loop of Lpp-OmpA through homology modelling (Figure 1). This part is under the control of lac promoter.
Figure 1. Homology modelling result of Lpp-OmpA-RGD. Red arrow shows the location of RGD motif.
Microscopy shows that E. coli expressed Lpp-OmpA-RGD induced by 0.1mM IPTG can bind to αVβ3-positive MDA-MB-231 cell line. Red arrow points the location of bacteria (Figure 2). But cannot bind to αVβ3-negative MCF7 cell line (Figure 3). We also use BBa_J36850 as a control. This strain cannot bind to αVβ3-positive MDA-MB-231 cell line (Figure 4) and αVβ3-negative MCF7 cell line (Figure 5). These results suggest that we successfully improve the part BBa_J36850. (Click here to see the method)
Figure 2. αVβ3-positive MDA-MB-231 cell line was incubated with E. coli which constructively expressed RFP and contained BBa_J36850. This improved part expressed RGD motif under the control of lac promoter.
Figure 3. αVβ3-negative MCF7 cell line was incubated with E. coli which constructive expressed RFP and contained BBa_J36850. This improved part expressed RGD motif under the control of lac promoter.
Figure 4. αVβ3-positive MDA-MB-231 cell line was incubated with E. coli which constructively expressed RFP and contained BBa_J36850.
Figure 5. αVβ3-negative MCF7 cell line was incubated with E. coli which constructively expressed RFP and contained BBa_J36850.
1. Grow Hela GSDMD KO cells in a humidified 37 °C, 5% CO2 tissue-culture incubator.
2. Count the cells using a hemocytometer. Seed in 24-well (5 × 10^4 per well) and grow overnight.
Preparation of Bacteria
1. Grow bacteria overnight 16 h in 2 mL LB in a 15-mL tube. Incubate at 37 °C in a shaking incubator (200 rpm).
2. Subculture bacteria by transferring 300 μL of the overnight culture into 5 mL of LB in a loosely capped 50-mL tube. Incubate at 37 °C in a shaking incubator (200 rpm) to late log phase.
3. Pellet 1 mL of the Salmonella subculture by centrifugation at 1000 g in a microfuge for 2 min at room temperature.
4. Remove 900 μL of supernatant and gently resuspend the pellet in 900 μL PBS.
Infection
1. Aspirate media and rinse the monolayer twice with PBS.
2. Inoculate cells with bacteria (MOI = 100) by adding bacteria directly to the cell-culture supernatant.
3. Incubate for 2 h at 37 °C in 5% CO2.
4. Aspirate media and wash
5. Add fresh GM containing 100 μg/mL gentamicin and 16 μg/mL incubate at 37 °C in 5% CO2 for 2 h.
6. Replace GM with fresh GM containing 20 μg/mL gentamicin for 1 h.
7.Add 16 μg/mL ATc for remainder of experiment.
Observation is taken after 5 min, 30 min, 1.5 h.
1 Park, S. H. et al. RGD Peptide Cell-Surface Display Enhances the Targeting and Therapeutic Efficacy of Attenuated Salmonella-mediated Cancer Therapy. Theranostics 6, 1672-1682, doi:10.7150/thno.16135 (2016).